Onglyza/Kombiglyze

Belonging to a new type of diabetic drugs(DPP-4), Onglyza(Saxagliptin) and Kombiglyze(Saxagliptin/Metformin), were released to the public even after concerns of cardiovascular side effects.  Both of these medications are used to help treat Type 2 diabetes.  Onglyza was released following FDA approval in 2009, with Kombiglyze being a medication containing metformin and saxagliptin being released a year later.

AstraZeneca, the makers of Onglyza, were ordered by the FDA to preform a post marketing study.  This was SAVOR, and studied over 16,000 users.  The results of this showed a 27% increase chance of being hospitalized due to heart failure as a result of taking the medication.

Both Onglyza and Kombiglyze, were required to add warnings about the risk of heart failure.  Additional, there are warnings about pancreatitis and pancreatic cancer

If you or a loved one has experienced any complications from taking the medication Onglyza or Kombiglyze, you may be entitled to financial compensation.  Fill out the form below to get started with your FREE case review.